Integrated analysis of CRLF2 signaling in acute lymphoblastic leukemia identifies Polo-like kinase 1 as a potential therapeutic target

Leuk Lymphoma. 2015 May;56(5):1524-7. doi: 10.3109/10428194.2014.963076. Epub 2014 Nov 5.

Authors

Tai-Chung Huang¹, Jevon Cutler, Shubhada Bharne, Jun Zhong, David Weinstock, Jeffrey Tyner, Ivana Gojo, Curt Civin, Akhilesh Pandey

Affiliation

¹ McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine , Baltimore, MD , USA.

No abstract available

Publication types

Letter

MeSH terms

Animals
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Cell Cycle Proteins / antagonists & inhibitors
Cell Cycle Proteins / metabolism*
Disease Models, Animal
Humans
Inhibitory Concentration 50
Molecular Targeted Therapy
Polo-Like Kinase 1
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Protein Serine-Threonine Kinases / antagonists & inhibitors
Protein Serine-Threonine Kinases / metabolism*
Proto-Oncogene Proteins / antagonists & inhibitors
Proto-Oncogene Proteins / metabolism*
Receptors, Cytokine / genetics
Receptors, Cytokine / metabolism*
Signal Transduction*
Xenograft Model Antitumor Assays

Substances

Antineoplastic Agents
CRLF2 protein, human
Cell Cycle Proteins
Protein Kinase Inhibitors
Proto-Oncogene Proteins
Receptors, Cytokine
Protein Serine-Threonine Kinases

Grants and funding